

Integrated System for Prevention, Diagnosis, and Treatment of Drug-Induced Oral Lesions in Patients with Comorbid Pathology

Ravshanova Odinabonu Temurzon kizi

Tashkent State Dental University

Annotation: Drug-induced oral lesions represent a serious medical problem in modern clinical practice, which becomes particularly relevant in the context of constant expansion of pharmacological arsenal and increasing life expectancy of the population. According to the World Health Organization (WHO), the incidence of adverse drug reactions in the oral cavity ranges from 3.2% to 12.8% among all hospitalized patients, while in patients with comorbid pathology this indicator increases to 18-25%.

Keywords: drug-induced stomatitis, comorbid pathology, xerostomia, drug-induced gingival hyperplasia.

Introduction. Modern pharmacotherapy is characterized by the use of complex treatment regimens including multiple drugs from various pharmacological groups. Polypharmacy, especially in elderly and senile patients with comorbidities, significantly increases the risk of drug-induced complications in the oral cavity. These complications range from relatively mild manifestations such as xerostomia and dysgeusia to severe conditions including ulcerative-necrotic lesions of the mucous membrane, drug-induced gingival hyperplasia, and toxic epidermal necrolysis with oral mucosal involvement.

It is incorrect to consider dental diseases exclusively as pathologies inherent only to the oral cavity. Recent studies show a direct relationship between oral health and general body condition. According to M. Farrell, Merkley V.F., Nafiza I. (2023), the average level of comorbidity among patients up to 35-40 years is 50-56%, while in the group over 50-55 years, the incidence of comorbid pathologies reaches 90%, and among patients over 75 years, almost all (98-99%) suffer from polycomorbid diseases.

According to data from S.I. Gazhva (2013), G.V. Gubanov (2015) and other researchers, in patients over 35 years, somatic pathology is detected in an average of 92.5%, with one-third showing signs of comorbidity. According to Bhateja (2012), A. Maryam et al. (2015), in a large population group of 1300 respondents, almost half of dental patients had comorbidities, with the severity of such pathologies increasing with age, and polycomorbidity was identified in 25% of those examined. Additionally, the authors emphasize that the number of diseases on average increases from 2.8 in younger patients to 6-7 in people over 75 years.

In our country, several researchers have conducted both experimental and clinical studies devoted to studying changes in the oral cavity related to the presence of comorbidities and their treatment process. Work has been performed on the diagnosis and treatment of oral mucosal lesions, and the microbiological state of the oral cavity in COVID-19 has been studied. However, questions regarding the prevalence of oral mucosal lesions caused by drug action have not yet been studied in detail.

Despite the achieved successes, problems of early diagnosis of oral diseases and development of therapeutic methods aimed at their pathogenesis remain relevant in our country. Moreover, considering the comorbidity of patient conditions and the necessity of using various medications, the question of implementing comprehensive dental treatment for this group of patients remains debatable. The dentist faces the task of developing methods for early and differential diagnosis, treatment, and monitoring of results in patients with comorbid pathology of internal organs.

Particular concern is caused by the fact that drug-induced oral lesions often remain unrecognized or are incorrectly interpreted as manifestations of the underlying disease, leading to delayed adequate

therapy and deterioration of patients' quality of life. According to results of epidemiological studies conducted in various countries, only 35-45% of cases of drug-induced oral lesions are diagnosed timely, which is due to insufficient awareness of physicians of various specialties regarding this problem.

The pathogenesis of drug-induced oral lesions is multifactorial and includes direct toxic effects of drugs on the mucous membrane, immune-mediated hypersensitivity reactions, disruption of the oral microbiome, changes in salivation and tissue metabolism. In patients with comorbid pathology, these mechanisms are complicated by interactions between various medications, disruption of pharmacokinetics and pharmacodynamics of drugs due to organ insufficiency, as well as increased tissue susceptibility to damaging effects.

Currently existing approaches to prevention, diagnosis, and treatment of drug-induced oral lesions are fragmentary and do not consider the complex interaction of risk factors in patients with multiple pathologies. Most clinical recommendations and protocols focus on treating individual types of lesions and do not provide a systematic approach to preventing their development. This leads to preventive measures often being insufficiently effective, and diagnosis and treatment being delayed and incomplete.

The modern trend toward personalized medicine requires the development of individualized approaches to managing patients at high risk of developing drug-induced oral lesions. This is particularly relevant for patients with comorbid pathology, where it is necessary to consider not only the spectrum of medications taken, but also the peculiarities of the course of primary and comorbid diseases, immune system status, genetic factors, and socio-economic aspects.

The interdisciplinary nature of the problem of drug-induced oral lesions requires close cooperation between physicians of various specialties – dentists, internists, clinical pharmacologists, dermatologists, oncologists, and others. However, in real clinical practice, such cooperation is often insufficient, leading to fragmentation of medical care and reduced effectiveness.

Economic aspects of this problem also deserve special attention. Drug-induced oral lesions lead to increased hospitalization duration, the need for additional diagnostic and therapeutic procedures, as well as reduced patient adherence to therapy for the underlying disease. According to pharmacoeconomic studies, total costs for treating complications related to adverse drug reactions in the oral cavity constitute a significant share in the structure of healthcare system expenditures in developed countries.

In the Republic of Uzbekistan, the problem of drug-induced oral lesions becomes particularly relevant in connection with healthcare system reform, introduction of new drugs, and improvement of approaches to treating chronic diseases. Increased accessibility of medical care and expansion of the nomenclature of applied medications create prerequisites for increased frequency of drug-induced complications, which requires the development of effective strategies for their prevention and treatment.

The oral cavity, based on its anatomical and functional features, is considered as one of the functional systems forming human body homeostasis. Unfortunately, when studying the medical history of patients seeking dental care, it was established that in more than 75-80% of patients, along with pathological changes in teeth, oral mucosa, and salivary gland tissues, one or several comorbid somatic pathologies are revealed. Oral health is one of the main indicators of general human health and quality of life, with the prevalence of oral diseases among the population aged 33-44 years being 65-98%. An urgent problem of modern dentistry is the improvement of methods for prevention and treatment of oral diseases in patients with somatic pathology.

Numerous scientific studies are being conducted worldwide devoted to studying the development of changes in the oral cavity resulting from treatment of somatic diseases. Treatment of somatic diseases includes the use of several medications belonging to various pharmacological groups. Based on this, it can be concluded that identified pathological signs in the oral cavity may be a consequence of the

treatment itself, effects of metabolic products of applied drugs, various preservatives and auxiliary substances in their composition, or local responsive reaction to the conducted therapy. Unfortunately, currently in patients with comorbidities, especially in comorbid conditions, polypharmacy often occurs due to simultaneous prescription of a large number of systemic medications. Based on this, the question remains relevant: what exactly causes changes in oral cavity tissues – comorbid diseases or the effects of drugs from various pharmacological groups.

Analysis of foreign and domestic literature indicates that, despite a significant volume of research devoted to individual aspects of drug-induced oral lesions, a holistic system combining preventive, diagnostic, and therapeutic approaches into a single integrated complex has not yet been created. This problem is particularly acute regarding patients with comorbid pathology, who constitute a significant share in the structure of medical care utilization.

Considering the above, the development of an integrated system for prevention, diagnosis, and treatment of drug-induced oral lesions in patients with comorbid pathology represents a relevant scientific and practical task, the solution of which will contribute to improving the quality and safety of medical care, improving disease prognosis and patients' quality of life.

The present study is aimed at creating a scientifically based system of comprehensive approach to this problem, including modern methods of risk stratification, early diagnosis, personalized preventive measures, and effective treatment regimens adapted for patients with various variants of comorbid pathology.

REFERENCES

1. Abdullaev A.M. Clinical and morphological features of drug-induced lesions of the oral mucosa / A.M. Abdullaev, S.R. Karimova // *Stomatology of Uzbekistan*. – 2021. – № 3. – P. 15-22.
2. Akhmedov R.Kh. Pharmacological aspects of xerostomia development in patients with arterial hypertension / R.Kh. Akhmedov, N.U. Tursunova // *Medical Journal of Uzbekistan*. – 2020. – № 4. – P. 78-84.
3. Ismailov B.S. Comorbid pathology and risk of developing dental complications of pharmacotherapy / B.S. Ismailov // *Clinical Pharmacology and Therapy*. – 2019. – Vol. 28, № 2. – P. 45-51.
4. Karimova L.A. Diagnosis and treatment of drug-induced gingival hyperplasia / L.A. Karimova, M.R. Rakhimov // *Periodontology*. – 2021. – № 1. – P. 32-38.
5. Mamatkulov O.R. Prevention of drug-induced oral lesions in oncological patients / O.R. Mamatkulov, Z.I. Usmanova // *Oncology and Radiology of Kazakhstan*. – 2020. – № 3. – P. 67-73.
6. Norbekov Zh.M. Personalized approach to managing patients with polypharmacy in dental practice / Zh.M. Norbekov // *New Day in Medicine*. – 2021. – № 4. – P. 125-132.
7. Rakhimova D.N. Drug interactions and development of orofacial complications / D.N. Rakhimova, A.K. Yuldashev // *Postgraduate Doctor*. – 2019. – Vol. 97, № 6. – P. 28-35.
8. Salimov O.A. Integrated approach to prevention of dental complications in patients with diabetes mellitus / O.A. Salimov, Sh.B. Kadyrova // *Endocrinology of Uzbekistan*. – 2020. – № 2. – P. 89-96.
9. Al-Dwairi Z.N. Drug-induced oral reactions in patients with chronic diseases / Z.N. Al-Dwairi, M.A. Alsmadi // *Int J Dent Hyg*. – 2020. – Vol. 18, № 2. – P. 203-210.
10. Baek S.K. Drug-induced oral and dental adverse effects / S.K. Baek, H.J. Kim, Y.J. Lee // *Hanyang Med Rev*. – 2019. – Vol. 39, № 4. – P. 215-222.
11. Bascones-Martinez A. Oral manifestations of drug reactions / A. Bascones-Martinez, M. Figuero-Ruiz // *Med Oral Patol Oral Cir Bucal*. – 2019. – Vol. 24, № 3. – P. e321-e330.

12. Chen Y.W. Drug-induced oral lichenoid reactions: A systematic review / Y.W. Chen, M.Y. Lin, P.C. Yang // *Oral Dis.* – 2021. – Vol. 27, № 5. – P. 1099-1110.
13. De Rossi S.S. Drug-induced gingival enlargement / S.S. De Rossi, P.B. Ferreira // *Periodontol* 2000. – 2020. – Vol. 83, № 1. – P. 92-106.
14. Femiano F. Drug-induced oral ulcerations / F. Femiano, N. Scully // *Oral Dis.* – 2019. – Vol. 25, № 6. – P. 1423-1436.
15. Garcia-Pola M. Risk factors for drug-induced oral manifestations / M. Garcia-Pola, J. Bagán, L. Cerero // *J Eur Acad Dermatol Venereol.* – 2021. – Vol. 35, № 4. – P. 891-899.